Skip to content

Fatty Liver Disease Collaborative Research in China

A Multi-center, Prospective Cohort Study on the Natural History of Fatty Liver Disease in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02391168
Acronym
FLDCR
Enrollment
3000
Registered
2015-03-18
Start date
2015-07-31
Completion date
2020-12-31
Last updated
2015-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver, Fatty Liver, Alcoholic, Non-alcoholic Fatty Liver Disease

Brief summary

A multi-center, prospective cohort study on the natural history of fatty liver disease in China

Detailed description

This is a multicenter, prospective and open-enrollment epidemiologic study. All the patients with liver biopsy-proven macrovesicular steatosis (\>5%) will be enrolled in the baseline cross-sectional analysis. Those who are either diagnosed as NAFLD or ALD, if meeting all the inclusion and exclusion criteria, will be enrolled in the following cohort study, will be followed up after 1 year, 3 years and 5 years with a visit window of +1 month.

Interventions

None listed

Sponsors

Unimed Scientific Inc.
CollaboratorINDUSTRY
Fatty Liver and Alcoholic Liver Disease Study Group, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Clinically diagnosed fatty liver disease, confirmed by liver biopsy. * Specific biopsy requirements: qualified biopsy specimen within 6 months, \>5% hepatocytes show macrovesicular steatosis under HE staining and X10 microscope. * Only patients with NAFLD or ALD are eligible for the 5-year follow-up cohort study. * Willing to participate in the long-term follow-up and cooperative. * Able to provide informed consent file.

Exclusion criteria

* Unable to provide informed consent. * Patients are eligible for baseline cross-sectional analysis but not eligible for the cohort section, if having any of the following condition: 1. Any end-stage liver disease. 2. Any malignant tumor. 3. Any infection of hepatitis virus or HIV. 4. Any congenital liver disease such as Wilson disease. 5. Any other serious disease of projected survival \< 5 years. 6. Combined NAFLD and ALD.

Design outcomes

Primary

MeasureTime frame
liver cirrhosis5 years

Secondary

MeasureTime frame
liver cancer5 years
liver failure5 years
type 2 diabetes5 years
cardiovascular and cerebrovascular events5 years
death5 years

Countries

China

Contacts

Primary ContactJiangao Fan, MD
fattyliver2004@126.com
Backup ContactChao Sun, MD
csun7682@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026